Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 135

1.

Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review.

Gudzune KA, Monroe AK, Sharma R, Ranasinghe PD, Chelladurai Y, Robinson KA.

Ann Intern Med. 2014 Apr 1;160(7):468-76. doi: 10.7326/M13-2526. Review.

PMID:
24514899
[PubMed - indexed for MEDLINE]
2.

Is combined lipid-regulating therapy safe and feasible for the very old patients with mixed dyslipidemia?

Zou X, Si QJ.

J Geriatr Cardiol. 2013 Dec;10(4):349-54. doi: 10.3969/j.issn.1671-5411.2013.04.014.

PMID:
24454328
[PubMed]
Free PMC Article
3.

[HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].

Bajnok L.

Orv Hetil. 2014 Jan 12;155(2):62-8. doi: 10.1556/OH.2014.29797. Review. Hungarian.

PMID:
24389322
[PubMed - indexed for MEDLINE]
4.

Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials.

Hamilton SJ, Watts GF.

Rev Diabet Stud. 2013 Summer-Fall;10(2-3):191-203. doi: 10.1900/RDS.2013.10.191. Epub 2013 Aug 10.

PMID:
24380092
[PubMed - in process]
5.

A young male with familial hypercholesterolemia.

Rahman A, Ahmed MU, Islam AK, Karim A, Sarker SA.

J Saudi Heart Assoc. 2012 Oct;24(4):261-4. doi: 10.1016/j.jsha.2012.06.264. Epub 2012 Aug 4.

PMID:
24174835
[PubMed]
Free PMC Article
6.

Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).

Albers JJ, Slee A, O'Brien KD, Robinson JG, Kashyap ML, Kwiterovich PO Jr, Xu P, Marcovina SM.

J Am Coll Cardiol. 2013 Oct 22;62(17):1575-9. doi: 10.1016/j.jacc.2013.06.051. Epub 2013 Aug 21.

PMID:
23973688
[PubMed - indexed for MEDLINE]
7.

Pharmacotherapies for lipid modification: beyond the statins.

Gotto AM Jr, Moon JE.

Nat Rev Cardiol. 2013 Oct;10(10):560-70. doi: 10.1038/nrcardio.2013.117. Epub 2013 Aug 20. Review.

PMID:
23959229
[PubMed - indexed for MEDLINE]
8.

Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients.

Le NA, Jin R, Tomassini JE, Tershakovec AM, Neff DR, Wilson PW.

J Am Heart Assoc. 2013 Aug 7;2(4):e000037. doi: 10.1161/JAHA.113.000037.

PMID:
23926117
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).

Guyton JR, Slee AE, Anderson T, Fleg JL, Goldberg RB, Kashyap ML, Marcovina SM, Nash SD, O'Brien KD, Weintraub WS, Xu P, Zhao XQ, Boden WE.

J Am Coll Cardiol. 2013 Oct 22;62(17):1580-4. doi: 10.1016/j.jacc.2013.07.023. Epub 2013 Jul 31.

PMID:
23916935
[PubMed - indexed for MEDLINE]
10.

Role of colesevelam in combination lipid-lowering therapy.

Jones MR, Nwose OM.

Am J Cardiovasc Drugs. 2013 Oct;13(5):315-23. doi: 10.1007/s40256-013-0037-0. Review.

PMID:
23913404
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia.

Lee P, Hegele RA.

Expert Opin Investig Drugs. 2013 Nov;22(11):1411-23. doi: 10.1517/13543784.2013.822485. Epub 2013 Jul 26. Review.

PMID:
23889692
[PubMed - indexed for MEDLINE]
12.

Beyond statins: lipid management to reduce cardiovascular risk.

Schuck RN, Mendys PM, Simpson RJ Jr.

Pharmacotherapy. 2013 Jul;33(7):754-64. doi: 10.1002/phar.1268. Epub 2013 Apr 18. Review.

PMID:
23606278
[PubMed - indexed for MEDLINE]
13.

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.

HPS2-THRIVE Collaborative Group.

Eur Heart J. 2013 May;34(17):1279-91. doi: 10.1093/eurheartj/eht055. Epub 2013 Feb 26.

PMID:
23444397
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

HDL deficiency due to a new insertion mutation (ApoA-INashua) and review of the literature.

Lee EY, Klementowicz PT, Hegele RA, Asztalos BF, Schaefer EJ.

J Clin Lipidol. 2013 Mar-Apr;7(2):169-73. doi: 10.1016/j.jacl.2012.10.011. Epub 2012 Nov 17. Review.

PMID:
23415437
[PubMed - indexed for MEDLINE]
15.

Dyslipidemia: management using optimal lipid-lowering therapy.

Ito MK.

Ann Pharmacother. 2012 Oct;46(10):1368-81. doi: 10.1345/aph.1R127. Epub 2012 Oct 2. Review.

PMID:
23032652
[PubMed - indexed for MEDLINE]
16.

Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes.

Matikainen N, Taskinen MR.

Curr Cardiol Rep. 2012 Dec;14(6):721-31. doi: 10.1007/s11886-012-0309-3. Review.

PMID:
22941588
[PubMed - indexed for MEDLINE]
17.

Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials.

Robinson JG, Wang S, Jacobson TA.

Am J Cardiol. 2012 Nov 15;110(10):1468-76. doi: 10.1016/j.amjcard.2012.07.007. Epub 2012 Aug 17. Review.

PMID:
22906895
[PubMed - indexed for MEDLINE]
18.

Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients.

Karalis DG, Victor B, Ahedor L, Liu L.

Cholesterol. 2012;2012:861924. doi: 10.1155/2012/861924. Epub 2012 Jul 25.

PMID:
22888414
[PubMed]
Free PMC Article
19.

Lipoprotein(a) particle concentration and lipoprotein(a) cholesterol assays yield discordant classification of patients into four physiologically discrete groups.

Konerman M, Kulkarni K, Toth PP, Jones SR.

J Clin Lipidol. 2012 Jul-Aug;6(4):368-73. doi: 10.1016/j.jacl.2012.01.004. Epub 2012 Jan 21.

PMID:
22836074
[PubMed - indexed for MEDLINE]
20.

The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges.

Ahmed MH, Al-Atta A, Hamad MA.

Expert Opin Pharmacother. 2012 Sep;13(13):1901-9. doi: 10.1517/14656566.2012.706604. Epub 2012 Jul 7. Review.

PMID:
22770622
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk